Complete Story
06/17/2026
Recent Oncology Related FDA Approvals and Expanded Indications
FDA approves Incyte's Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
FDA approves AstraZeneca's Imfinzi™ (durvalumab) in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer
FDA approves AbbVie's DECNUPAZ™ (pivekimab sunirine-pvzy) for treatment of adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
FDA approves AstraZeneca's ENHERTU–THP as a neoadjuvant therapy for patients with HER2+ (IHC 3+ or ISH+) early breast cancer (Stage II or III)
FDA Approves AstraZeneca's ENHERTU as a post-neoadjuvant treatment for patients with HER2+ (IHC 3+ or ISH+) early breast cancer who have residual invasive disease
More InfoReport Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
